Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
FMS Stock Summary
In the News
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.
Fresenius Medical (FMS) Q4 Earnings Beat, Operating Margin Up
Fresenius Medical's (FMS) fourth-quarter revenues suffer due to unfavorable currency movement. However, the company?
Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcript
Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System
Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.
Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio
Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius plans to sell rehabilitation care clinics - FAZ
Fresenius has hired UBS to manage the sale of its rehabilitation care clinic business as the German healthcare group focuses on core activities, Frankfurter Allgemeine Zeitung reported on Friday, citing financial sources.
Fresenius Medical Care says data on 500,000 people stolen in U.S.
Dialysis group Fresenius Medical Care said on Wednesday that data including medical records on 500,000 patients and former patients were stolen from a U.S. subsidiary's database.
Fresenius Medical (FMS) Ups '23 Outlook After Legal Settlement
Fresenius Medical (FMS) wins legal dispute against the U.S. government. Both revenues and operating income will benefit from the settlement agreement.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
FMS Financial details
FMS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 28.87 | 30.37 | 30.07 | 33.07 | 33.15 | |
Net income per share | 1.98 | 1.98 | 1.65 | 1.15 | 0.85 | |
Operating cash flow per share | 4.24 | 7.2 | 4.25 | 3.69 | 4.48 | |
Free cash flow per share | 0.54 | 3.65 | 1.38 | 1.29 | 3.31 | |
Cash per share | 1.88 | 2.11 | 2.76 | 2.46 | 2.62 | |
Book value per share | 21.85 | 20.97 | 23.86 | 26.34 | 23.21 | |
Tangible book value per share | -3.66 | -3.42 | -3.14 | -3.17 | -2.02 | |
Share holders equity per share | 21.85 | 20.97 | 23.86 | 26.34 | 23.21 | |
Interest debt per share | 23.58 | 21.75 | 23.34 | 23.14 | 21.11 | |
Market cap | 19.81B | 19.99B | 16.79B | 8.98B | 11.28B | |
Enterprise value | 32.58B | 31.29B | 28.63B | 20.92B | 21.93B | |
P/E ratio | 16.51 | 17.17 | 17.32 | 13.34 | 22.61 | |
Price to sales ratio | 1.13 | 1.12 | 0.95 | 0.46 | 0.58 | |
POCF ratio | 7.72 | 4.72 | 6.75 | 4.15 | 4.29 | |
PFCF ratio | 60.21 | 9.32 | 20.83 | 11.88 | 5.8 | |
P/B Ratio | 1.5 | 1.62 | 1.2 | 0.58 | 0.83 | |
PTB ratio | 1.5 | 1.62 | 1.2 | 0.58 | 0.83 | |
EV to sales | 1.86 | 1.75 | 1.63 | 1.08 | 1.13 | |
Enterprise value over EBITDA | 14.15 | 13.52 | 14.87 | 13.24 | 6.38 | |
EV to operating cash flow | 12.69 | 7.39 | 11.5 | 9.65 | 8.34 | |
EV to free cash flow | 99.04 | 14.59 | 35.52 | 27.67 | 11.28 | |
Earnings yield | 0.06 | 0.06 | 0.06 | 0.07 | 0.04 | |
Free cash flow yield | 0.02 | 0.11 | 0.05 | 0.08 | 0.17 | |
Debt to equity | 1.04 | 1 | 0.95 | 0.86 | 0.88 | |
Debt to assets | 0.42 | 0.39 | 0.39 | 0.37 | 0.36 | |
Net debt to EBITDA | 5.55 | 4.88 | 6.15 | 7.56 | 3.1 | |
Current ratio | 1.02 | 1.18 | 1.1 | 1.27 | 1.42 | |
Interest coverage | 1.45 | 1.29 | 0.85 | -0.72 | 4.46 | |
Income quality | 1.78 | 2.95 | 2.04 | 2.42 | 5.27 | |
Dividend Yield | 0.02 | 0.02 | 0.02 | 0.04 | 0.03 | |
Payout ratio | 0.3 | 0.3 | 0.4 | 0.59 | 0.66 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Intangibles to total assets | 0.47 | 0.45 | 0.46 | 0.48 | 0.47 | |
Capex to operating cash flow | -0.87 | -0.49 | -0.68 | -0.65 | -0.26 | |
Capex to revenue | -0.13 | -0.12 | -0.1 | -0.07 | -0.04 | |
Capex to depreciation | -1.4 | -1.17 | -1.04 | -0.77 | -0.39 | |
Stock based compensation to revenue | 0 | -0.11 | -0.1 | 0 | 0.02 | |
Graham number | 31.22 | 30.56 | 29.8 | 26.09 | 21.07 | |
ROIC | 0.02 | 0.02 | 0.01 | -0.01 | 0.03 | |
Return on tangible assets | 0.07 | 0.07 | 0.05 | 0.04 | 0.03 | |
Graham Net | -24.38 | -24.58 | -25.3 | -25.05 | -22.88 | |
Working capital | 157.77M | 1.12B | 709M | 1.74B | 2.59B | |
Tangible asset value | -2.22B | -2.01B | -1.84B | -1.86B | -1.19B | |
Net current asset value | -12.54B | -12.08B | -12.42B | -12.1B | -10.4B | |
Invested capital | 1.04 | 1 | 0.95 | 0.86 | 0.88 | |
Average receivables | 3.87B | 3.79B | 3.76B | 3.97B | 4.05B | |
Average payables | 815.12M | 831.29M | 842.46M | 894.43M | 908.24M | |
Average inventory | 1.57B | 1.78B | 1.97B | 2.17B | 2.24B | |
Days sales outstanding | 82.9 | 73.97 | 80.93 | 75.86 | 76.19 | |
Days payables outstanding | 25.23 | 24.51 | 24.96 | 24.13 | 22.24 | |
Days of inventory on hand | 50.25 | 56.14 | 59.31 | 59.49 | 54.75 | |
Receivables turnover | 4.4 | 4.93 | 4.51 | 4.81 | 4.79 | |
Payables turnover | 14.46 | 14.89 | 14.63 | 15.13 | 16.41 | |
Inventory turnover | 7.26 | 6.5 | 6.15 | 6.14 | 6.67 | |
ROE | 0.09 | 0.09 | 0.07 | 0.04 | 0.04 | |
Capex per share | -3.7 | -3.55 | -2.87 | -2.41 | -1.17 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 8.52 | 8.02 | 8.22 | 8.41 | 17 | |
Net income per share | 0.33 | 0.23 | 0.24 | 0.14 | 0.64 | |
Operating cash flow per share | 1.02 | 0.24 | 1.72 | 1.29 | 2.45 | |
Free cash flow per share | 0.29 | 0 | 1.45 | 1.06 | 1.6 | |
Cash per share | 2.46 | 2.09 | 2.32 | 2.65 | 5.25 | |
Book value per share | 26.33 | 23.56 | 23.05 | 23.87 | 46.42 | |
Tangible book value per share | -3.17 | -2.84 | -3.23 | -2.35 | -4.04 | |
Share holders equity per share | 26.33 | 23.56 | 23.05 | 23.87 | 46.42 | |
Interest debt per share | 22.69 | 22.77 | 22.44 | 22.3 | 41.36 | |
Market cap | 8.99B | 11.44B | 12.92B | 12.06B | 5.64B | |
Enterprise value | 20.93B | 23.48B | 24.63B | 23.48B | 16.29B | |
P/E ratio | 11.58 | 21.37 | 23.01 | 35.74 | 7.5 | |
Price to sales ratio | 1.8 | 2.43 | 2.68 | 2.44 | 1.13 | |
POCF ratio | 14.98 | 80.1 | 12.83 | 15.87 | 7.84 | |
PFCF ratio | 53.18 | 16.25K | 15.17 | 19.36 | 12.03 | |
P/B Ratio | 0.58 | 0.83 | 0.96 | 0.86 | 0.41 | |
PTB ratio | 0.58 | 0.83 | 0.96 | 0.86 | 0.41 | |
EV to sales | 4.19 | 4.99 | 5.1 | 4.76 | 3.27 | |
Enterprise value over EBITDA | 55.51 | 32.61 | 28.51 | 29.23 | 18.5 | |
EV to operating cash flow | 34.88 | 164.41 | 24.45 | 30.91 | 22.65 | |
EV to free cash flow | 123.82 | 33.36K | 28.91 | 37.69 | 34.74 | |
Earnings yield | 0.02 | 0.01 | 0.01 | 0.01 | 0.03 | |
Free cash flow yield | 0.02 | 0 | 0.07 | 0.05 | 0.08 | |
Debt to equity | 0.86 | 0.96 | 0.97 | 0.93 | 0.88 | |
Debt to assets | 0.37 | 0.37 | 0.37 | 0.36 | 0.36 | |
Net debt to EBITDA | 31.67 | 16.72 | 13.55 | 14.22 | 12.09 | |
Current ratio | 1.27 | 1.32 | 1.26 | 1.37 | 1.42 | |
Interest coverage | -1.18 | 2.76 | 3.41 | 2.85 | 5.16 | |
Income quality | 3.09 | 1.07 | 5.17 | 5.17 | 3.82 | |
Dividend Yield | 0 | 0 | 0.03 | 0 | 0 | |
Payout ratio | 0 | 0 | 2.34 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Intangibles to total assets | 0.48 | 0.48 | 0.48 | 0.47 | 0.47 | |
Capex to operating cash flow | -0.72 | -1 | -0.15 | -0.18 | -0.35 | |
Capex to revenue | -0.09 | -0.03 | -0.03 | -0.03 | -0.05 | |
Capex to depreciation | -0.87 | -0.32 | -0.36 | -0.3 | -0.59 | |
Stock based compensation to revenue | 0 | 0 | -0.02 | -0.05 | 0.04 | |
Graham number | 13.99 | 11 | 11.14 | 8.79 | 25.86 | |
ROIC | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
Return on tangible assets | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
Graham Net | -25.03 | -25.37 | -25.16 | -25.07 | -45.77 | |
Working capital | 1.74B | 2.07B | 1.72B | 2.43B | 2.59B | |
Tangible asset value | -1.86B | -1.67B | -1.89B | -1.38B | -1.19B | |
Net current asset value | -12.1B | -11.71B | -11.68B | -11.15B | -10.4B | |
Invested capital | 0.86 | 0.96 | 0.97 | 0.93 | 0.88 | |
Average receivables | 4B | 4.01B | 3.82B | 3.68B | 3.89B | |
Average payables | 920.13M | 922.45M | 866.39M | 831.99M | 864.96M | |
Average inventory | 2.35B | 2.31B | 2.33B | 2.32B | 2.24B | |
Days sales outstanding | 72.61 | 76.44 | 68.01 | 67.72 | 73.27 | |
Days payables outstanding | 22.97 | 23.13 | 20.32 | 20.51 | 21.9 | |
Days of inventory on hand | 56.63 | 58.94 | 57.93 | 55.93 | 53.91 | |
Receivables turnover | 1.24 | 1.18 | 1.32 | 1.33 | 1.23 | |
Payables turnover | 3.92 | 3.89 | 4.43 | 4.39 | 4.11 | |
Inventory turnover | 1.59 | 1.53 | 1.55 | 1.61 | 1.67 | |
ROE | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Capex per share | -0.73 | -0.24 | -0.26 | -0.23 | -0.85 |
FMS Frequently Asked Questions
What is Fresenius Medical Care AG & Co. KGaA stock symbol ?
Fresenius Medical Care AG & Co. KGaA is a DE stock and trading under the symbol FMS
Is Fresenius Medical Care AG & Co. KGaA buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $19.35. The lowest prediction is $11.7 and the highest is $27
What is FMS stock prediction ?
What is Fresenius Medical Care AG & Co. KGaA stock quote today ?
Fresenius Medical Care AG & Co. KGaA stock price is $19.28 today.
Is Fresenius Medical Care AG & Co. KGaA stock public?
Yes, Fresenius Medical Care AG & Co. KGaA is a publicly traded company.